10,000 Shares in Sensus Healthcare, Inc. (NASDAQ:SRTS) Purchased by Chapin Davis Inc.

Chapin Davis Inc. bought a new stake in Sensus Healthcare, Inc. (NASDAQ:SRTS) during the 2nd quarter, Holdings Channel reports. The firm bought 10,000 shares of the company’s stock, valued at approximately $53,000.

Several other hedge funds have also made changes to their positions in SRTS. Creekmur Asset Management LLC acquired a new stake in shares of Sensus Healthcare during the 4th quarter worth about $83,000. Hillsdale Investment Management Inc. acquired a new position in Sensus Healthcare during the 1st quarter worth $155,000. Finally, Sachetta LLC purchased a new stake in Sensus Healthcare during the 4th quarter worth about $247,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Stock Up 0.8 %

Shares of NASDAQ SRTS opened at $6.53 on Monday. The business has a 50-day moving average price of $5.76 and a 200 day moving average price of $4.77. The stock has a market cap of $107.03 million, a PE ratio of 22.35 and a beta of 1.00. Sensus Healthcare, Inc. has a 52-week low of $1.79 and a 52-week high of $6.97.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.07. The business had revenue of $9.24 million for the quarter, compared to analyst estimates of $7.00 million. Sensus Healthcare had a net margin of 18.27% and a return on equity of 13.78%. During the same period last year, the firm posted ($0.02) earnings per share. Sell-side analysts anticipate that Sensus Healthcare, Inc. will post 0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SRTS. Maxim Group increased their target price on Sensus Healthcare from $7.00 to $10.00 and gave the company a “buy” rating in a report on Friday, May 10th. Roth Capital raised shares of Sensus Healthcare to a “strong-buy” rating in a report on Friday, July 12th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Sensus Healthcare in a report on Monday, August 12th.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.